33 research outputs found

    Effects of recombinant human parathyroid hormone on the anabolic window and acceleration of lower extremity stress fracture healing

    Full text link
    Thesis (M.A.)--Boston UniversityBACKGROUND: Stress fractures are one of the more severe overuse injuries and occur more frequently in women than men. Location and severity of stress fractures vary according to the sport and intensity of physical activity and most commonly involve the lower extremities. The treatment period may extend beyond 12 weeks based on the severity of the stress fracture and physical activity of the patient. Although data are sparse, there is an evolving interest in using systemic medical interventions to potentially improve or accelerate stress fracture repair. Intermittent administration of human recombinant parathyroid hormone (PTH) (1-34) (Teriparatide) is a FDA-approved anabolic treatment used to treat osteoporosis in men and women and reduce fracture risk in postmenopausal women. Although there may be potential benefits of systemic teriparatide therapy to hasten the healing of fractures, there only a few randomized, controlled studies at present. OBJECTIVES: To determine in this randomized, placebo-controlled study whether teriparatide can increase the anabolic window in premenopausal women with lower extremity stress fractures and can hasten the healing process, as assessed by Magnetic Resonance Imaging (MRI). Specifically, we will evaluate: 1) Whether bone formation markers increases more rapidly than resorption markers in response to daily teriparatide (20 μg) at 4 and 8 weeks and of the anabolic window, using the area under the curve between percent changes in biomarkers of formation over resorption over time, and 2) whether there is acceleration of the stress fracture healing, as assessed by MRI images. [TRUNCATED

    Short-term effects of teriparatide versus placebo on bone biomarkers, structure, and fracture healing in women with lower-extremity stress fractures: A pilot study

    Get PDF
    Aims In this pilot, placebo-controlled study, we evaluated whether brief administration of teriparatide (TPTD) in premenopausal women with lower-extremity stress fractures would increase markers of bone formation in advance of bone resorption, improve bone structure, and hasten fracture healing according to magnetic resonance imaging (MRI). Methods: Premenopausal women with acute lower-extremity stress fractures were randomized to injection of TPTD 20-µg subcutaneous (s.c.) (n = 6) or placebo s.c. (n = 7) for 8 weeks. Biomarkers for bone formation N-terminal propeptide of type I procollagen (P1NP) and osteocalcin (OC) and resorption collagen type-1 cross-linked C-telopeptide (CTX) and collagen type 1 cross-linked N-telopeptide (NTX) were measured at baseline, 4 and 8 weeks. The area between the percent change of P1NP and CTX over study duration is defined as the anabolic window. To assess structural changes, peripheral quantitative computed topography (pQCT) was measured at baseline, 8 and 12 weeks at the unaffected tibia and distal radius. The MRI of the affected bone assessed stress fracture healing at baseline and 8 weeks. Results: After 8 weeks of treatment, bone biomarkers P1NP and OC increased more in the TPTD- versus placebo-treated group (both p ≤ 0.01), resulting in a marked anabolic window (p ≤ 0.05). Results from pQCT demonstrated that TPTD-treated women showed a larger cortical area and thickness compared to placebo at the weight bearing tibial site, while placebo-treated women had a greater total tibia and cortical density. No changes at the radial sites were observed between groups. According to MRI, 83.3% of the TPTD- and 57.1% of the placebo-treated group had improved or healed stress fractures (p = 0.18). Conclusions: In this randomized, pilot study, brief administration of TPTD showed anabolic effects that TPTD may help hasten fracture healing in premenopausal women with lower-extremity stress fractures. Larger prospective studies are warranted to determine the effects of TPTD treatment on stress fracture healing in premenopausal women

    Identifying fetal alcohol spectrum disorder among South African children at aged 1 and 5 years

    No full text
    BackgroundFetal Alcohol Spectrum Disorders (FASD) are a global health concern. Early intervention mitigates deficits, yet early diagnosis remains challenging. We examined whether children can be screened and meet diagnoses for FASD at 1.5 years compared to 5 years post-birth.MethodsA population cohort of pregnant women in 24 neighborhoods (N = 1258) was recruited and 84.5 %-96 % were reassessed at two weeks post-birth, 0.5 years, 1.5 years, 3 years, and 5 years later. A two-step process was followed to diagnose FASD; first, a paraprofessional screened the children and then a physician evaluated the child. We evaluated FASD symptoms at 1.5 vs. 5 years. We also examined maternal differences in children receiving a positive FASD screening (n = 160) with those who received a negative FASD screening.ResultsScreening positive for FASD more than doubled from 1.5 years to 5 years (from 6.8 % to 14.8 %). About one quarter of children who screened positive and were evaluated by a physician, were diagnosed as having a FASD. However, half did not complete the 2nd stage screening. Compared to mothers of children with a negative FASD screening, mothers of children with a positive FASD screening were less likely to have a high school education and more likely to have lower incomes, have experienced interpersonal partner violence, and have a depressed mood. Mothers of children who did not follow up for a 2nd stage physician evaluation were more like to live in informal housing compared to those who followed-up (81.3 % vs. 62.5 %, p = 0.014).ConclusionsWe found that children can be screened and diagnosed for FASD at 1.5 and 5 years. As FASD characteristics develop over time, repeated screenings are necessary to identify all affected children and launch preventive interventions. Referrals for children to see a physician to confirm diagnosis and link children to care remains a challenge. Integration with the primary healthcare system might mitigate some of those difficulties
    corecore